Log in

Relevant bibliographies by topics / Lungs – Cancer – Gene therapy / Journal articles

To see the other types of publications on this topic, follow the link: Lungs – Cancer – Gene therapy.

Journal articles on the topic 'Lungs – Cancer – Gene therapy'

Author: Grafiati

Published: 4 June 2021

Last updated: 13 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Lungs – Cancer – Gene therapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Frederiksen, Klaus Stensgaard, Andreas Petri, Niels Abrahamsen, and Hans Skovgaard Poulsen. "Gene therapy for lung cancer." Lung Cancer 23, no. 3 (1999): 191–207. http://dx.doi.org/10.1016/s0169-5002(99)00012-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Lara-Guerra, Humberto, and Jack A. Roth. "Gene Therapy for Lung Cancer." Critical Reviews™ in Oncogenesis 21, no. 1-2 (2016): 115–24. http://dx.doi.org/10.1615/critrevoncog.2016016084.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Toloza, Eric M. "Gene Therapy for Lung Cancer." Thoracic Surgery Clinics 16, no. 4 (2006): 397–419. http://dx.doi.org/10.1016/j.thorsurg.2006.08.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Haura, Eric B., Eduardo Sotomayor, and Scott J. Antonia. "Gene Therapy for Lung Cancer." Molecular Biotechnology 25, no. 2 (2003): 139–48. http://dx.doi.org/10.1385/mb:25:2:139.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Dubinett, Steven M., Patrice W. Miller, Sherven Sharma, and Raj K. Batra. "GENE THERAPY FOR LUNG CANCER." Hematology/Oncology Clinics of North America 12, no. 3 (1998): 569–94. http://dx.doi.org/10.1016/s0889-8588(05)70009-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Toloza, Eric M., Michael A. Morse, and H. Kim Lyerly. "Gene therapy for lung cancer." Journal of Cellular Biochemistry 99, no. 1 (2006): 1–22. http://dx.doi.org/10.1002/jcb.20851.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Antonia, Scott J., and Eduardo Sotomayor. "Gene therapy for lung cancer." Current Opinion in Oncology 12, no. 2 (2000): 138–42. http://dx.doi.org/10.1097/00001622-200003000-00007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Toloza, Eric M. "Gene Therapy for Lung Cancer." Seminars in Thoracic and Cardiovascular Surgery 17, no. 3 (2005): 205–12. http://dx.doi.org/10.1053/j.semtcvs.2005.08.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Woll, P. J., and I. R. Hart. "Gene therapy for lung cancer." Annals of Oncology 6 (1995): S73—S78. http://dx.doi.org/10.1093/annonc/6.suppl_1.s73.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Lee, C. T., H. L. Chen, and D. P. Carbone. "Gene therapy for lung cancer." Annals of Oncology 6 (1995): S61—S63. http://dx.doi.org/10.1093/annonc/6.suppl_3.s61.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Swisher, Stephen G., and Jack A. Roth. "Gene therapy in lung cancer." Current Oncology Reports 2, no. 1 (2000): 64–70. http://dx.doi.org/10.1007/s11912-000-0012-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Daniel, Jonathan C., and W. Roy Smythe. "Gene therapy of lung cancer." Seminars in Surgical Oncology 21, no. 3 (2003): 196–204. http://dx.doi.org/10.1002/ssu.10038.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Mosca, Paul J., Michael A. Morse, Thomas A. D'Amico, Jeffrey Crawford, and H. Kim Lyerly. "Gene Therapy for Lung Cancer." Clinical Lung Cancer 1, no. 3 (2000): 218–26. http://dx.doi.org/10.3816/clc.2000.n.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Bardoliwala, Denish, Ankit Javia, Saikat Ghosh, Ambikanandan Misra, and Krutika Sawant. "Formulation and clinical perspectives of inhalation-based nanocarrier delivery: a new archetype in lung cancer treatment." Therapeutic Delivery 12, no. 5 (2021): 397–418. http://dx.doi.org/10.4155/tde-2020-0101.

Full text

Abstract:

Despite tremendous research in targeted delivery and specific molecular inhibitors (gene delivery), cytotoxic drug delivery through inhalation has been seen as a core part in the treatment of the lung cancer. Inhalation delivery provides a high dose of the drug directly to the lungs without affecting other body organs, increasing the therapeutic ratio. This article reviews the research performed over the last several decades regarding inhalation delivery of various cancer therapeutics for the treatment of lung cancer. Nevertheless, pulmonary administration of nanocarrier-based cancer therapeut

APA, Harvard, Vancouver, ISO, and other styles

15

Hege, Kristen M., and David P. Carbone. "Lung cancer vaccines and gene therapy." Lung Cancer 41 (August 2003): 103–13. http://dx.doi.org/10.1016/s0169-5002(03)00153-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Roth, J. A., S. G. Swisher, D. D. Lawrence, et al. "Gene therapy strategies for lung cancer." Lung Cancer 18 (August 1997): 141. http://dx.doi.org/10.1016/s0169-5002(97)83954-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Swisher, Stephen G., and Jack A. Roth. "p53 Gene therapy for lung cancer." Current Oncology Reports 4, no. 4 (2002): 334–40. http://dx.doi.org/10.1007/s11912-002-0009-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Tursz, T. "610 Gene therapy in lung cancer." European Journal of Cancer 31 (November 1995): S129. http://dx.doi.org/10.1016/0959-8049(95)95864-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Vasic, Ljiljana. "Molecular targets and gene therapy of lung cancer." Archive of Oncology 17, no. 1-2 (2009): 19–24. http://dx.doi.org/10.2298/aoo0902019v.

Full text

Abstract:

Lung cancer is of great interest in human pathology because its apparent aggressiveness cannot be stopped by applied treatment procedures. The lack of highly specific screening tests prevents an early diagnosis of the disease. Insidious beginning and diverse and unclear clinical picture are responsible for the fact that most cases are diagnosed at advanced stages. An increasing number of patients and a short length of survival are additional factors that make this disease an imperative in the clinical practice, while vague and mutually dependent etiological factors represent a challenge in lab

APA, Harvard, Vancouver, ISO, and other styles

20

Khan, Sajad, Shahid Ali, and Muhammad. "Exhaustive Review on Lung Cancers: Novel Technologies." Current Medical Imaging Formerly Current Medical Imaging Reviews 15, no. 9 (2019): 873–83. http://dx.doi.org/10.2174/1573405615666181128124528.

Full text

Abstract:

Background:Lung cancers or (Bronchogenic-Carcinomas) are the disease in certain parts of the lungs in which irresistible multiplication of abnormal cells leads to the inception of a tumor. Lung cancers consisting of two substantial forms based on the microscopic appearance of tumor cells are: Non-Small-Cell-Lung-Cancer (NSCLC) (80 to 85%) and Small-Cell-Lung-Cancer (SCLC) (15 to 20%).Discussion:Lung cancers are existing luxuriantly across the globe and the most prominent cause of death in advanced countries (USA & UK). There are many causes of lung cancers in which the utmost imperative as

APA, Harvard, Vancouver, ISO, and other styles

21

Fujiwara, Toshiyoshi, and Noriaki Tanaka. "Adenoviral p53 Gene Therapy for Lung Cancer." Okayama Igakkai Zasshi (Journal of Okayama Medical Association) 119, no. 3 (2008): 229–34. http://dx.doi.org/10.4044/joma.119.229.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Vachani, Anil, Edmund Moon, Elliot Wakeam, and Steven M. Albelda. "Gene Therapy for Mesothelioma and Lung Cancer." American Journal of Respiratory Cell and Molecular Biology 42, no. 4 (2010): 385–93. http://dx.doi.org/10.1165/rcmb.2010-0026rt.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Albelda, Steven M. "Gene Therapy for Lung Cancer and Mesothelioma." Chest 111, no. 6 (1997): 144S—149S. http://dx.doi.org/10.1378/chest.111.6_supplement.144s.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Jenks, S. "RAC Conditionally Approves Lung Cancer Gene Therapy." JNCI Journal of the National Cancer Institute 86, no. 13 (1994): 964–65. http://dx.doi.org/10.1093/jnci/86.13.964.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Lim, SYM, M. Alshagga, CE Ong, JY Chieng, and Y. Pan. "Cytochrome P450 4B1 (CYP4B1) as a target in cancer treatment." Human & Experimental Toxicology 39, no. 6 (2020): 785–96. http://dx.doi.org/10.1177/0960327120905959.

Full text

Abstract:

Cytochrome P450 4B1 (CYP4B1) plays crucial roles in biotransforming of xenobiotics. Its predominant extrahepatic expression has been associated with certain tissue-specific toxicities. However, the expressions of CYP4B1 in various cancers and hence their potential roles in cancer development were inclusive. In this work, existing knowledge on expression and regulation of CYP4B1 gene and protein, catalysis of CYP4B1, association of CYP4B1 with cancers, contradicting findings about human CYP4B1 activities as well as the employing CYP4B1 in suicide gene approach for cancer treatment were reviewed

APA, Harvard, Vancouver, ISO, and other styles

26

&NA;. "Milestone reached in gene therapy for lung cancer." Inpharma Weekly &NA;, no. 1061 (1996): 11. http://dx.doi.org/10.2165/00128413-199610610-00019.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Larkin, Marilynn. "Promising results reported for lung cancer gene therapy." Lancet 348, no. 9028 (1996): 671. http://dx.doi.org/10.1016/s0140-6736(05)65076-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Jenks, Susan. "Gene Therapy for Lung Cancer Still On Hold." JNCI: Journal of the National Cancer Institute 86, no. 7 (1994): 486. http://dx.doi.org/10.1093/jnci/86.7.486.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Kohno, Takashi, Koji Tsuta, Katsuya Tsuchihara, Takashi Nakaoku, Kiyotaka Yoh, and Koichi Goto. "RETfusion gene: Translation to personalized lung cancer therapy." Cancer Science 104, no. 11 (2013): 1396–400. http://dx.doi.org/10.1111/cas.12275.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Vattemi, E., and P. P. Claudio. "Current status of gene therapy for lung cancer." Drugs of the Future 30, no. 10 (2005): 1017. http://dx.doi.org/10.1358/dof.2005.030.10.946206.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Pedersen, Nina, Thomas T. Poulsen, Mikkel W. Pedersen, Michael S. Lan, Mary B. Breslin, and Hans S. Poulsen. "328. Transcriptionally Targeted Cancer Gene Therapy for Small Cell Lung Cancer." Molecular Therapy 13 (2006): S125. http://dx.doi.org/10.1016/j.ymthe.2006.08.385.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Zheng, Xiaohu, Weihua Xiao, and Zhigang Tian. "869 Anti-LunX targeting therapy for lung cancer." Journal for ImmunoTherapy of Cancer 8, Suppl 3 (2020): A921. http://dx.doi.org/10.1136/jitc-2020-sitc2020.0869.

Full text

Abstract:

BackgroundThe identification of novel therapeutic targets in lung cancer for the generation of targeted drugs is an urgent challenge. Lung-specific X (LunX) is a member of the palate, lung, and nasal epithelium clone (PLUNC) protein family. Some reports have suggested that the human PLUNC gene (also named LUNX) might be a potential marker for NSCLC, and PLUNC mRNA has been identified in peripheral blood and mediastinal lymph nodes from NSCLC patients.It is unclear whether LunX expression is associated with the pathological type and pathological severity in lung cancer patients. The utility of

APA, Harvard, Vancouver, ISO, and other styles

33

Martiniello-Wilks, Rosetta, Stephen R. Larsen, Stephane Flamant, Jessamy C. Tiffen, Charles G. Bailey, and John E. J. Rasko. "Mesenchymal Stem Cells as Suicide Gene Therapy Vehicles for Organ-Confined and Metastatic Prostate Cancer (PCa)." Blood 110, no. 11 (2007): 5148. http://dx.doi.org/10.1182/blood.v110.11.5148.5148.

Full text

Abstract:

Abstract The efficacy of mesenchymal stem cells (MSC) is currently being examined as a clinical regenerative medicine for multiple sclerosis, cirrhosis, liver disease, tibial fractures, heart failure and graft versus host disease. MSC display an inherent tumor-tropic property that has been exploited for the targeted delivery of therapeutic genes to metastatic melanoma, glioma, breast and colon carcinoma in animal models. Advantages of using MSC include their ability for: self-renewal, ease of propagation and gene modification ex vivo; secretion of high levels of therapeutic protein; evasion of

APA, Harvard, Vancouver, ISO, and other styles

34

Christensen, Camilla L., Roza Zandi, Torben Gjetting, Frederik Cramer, and Hans S. Poulsen. "Specifically targeted gene therapy for small-cell lung cancer." Expert Review of Anticancer Therapy 9, no. 4 (2009): 437–52. http://dx.doi.org/10.1586/era.09.10.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Roth, Jack A., John D. Minna, Lin X. Ji, and Rajagopal Ramesh. "E-63. New gene targets for lung cancer therapy." Lung Cancer 41 (August 2003): S79. http://dx.doi.org/10.1016/s0169-5002(03)90470-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

&NA;. "Interleukin-2 gene therapy has potential in lung cancer." Inpharma Weekly &NA;, no. 1050 (1996): 8. http://dx.doi.org/10.2165/00128413-199610500-00016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Christensen, Camilla Laulund, Nina Pedersen, and Hans Skovgaard Poulsen. "46Targeted suicide gene therapy for small cell lung cancer." APMIS 116, no. 5 (2008): 412–13. http://dx.doi.org/10.1111/j.1600-0463.2008.001165_2.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Zhang, Mei, You-Kyoung Kim, Pengfei Cui, et al. "Folate-conjugated polyspermine for lung cancer–targeted gene therapy." Acta Pharmaceutica Sinica B 6, no. 4 (2016): 336–43. http://dx.doi.org/10.1016/j.apsb.2016.03.010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Kim, Jung Sun, and Eun Joo Kang. "Targeted Therapy for Non-Small Cell Lung Cancer." Korean Journal of Medicine 95, no. 2 (2020): 78–88. http://dx.doi.org/10.3904/kjm.2020.95.2.78.

Full text

Abstract:

Treatment of progressive non-small cell lung cancer (NSCLC) has advanced remarkably, due in part to the development of targeted therapies. Several gene alterations, including EGFR, ALK, ROS1, and BRAF, play important roles in carcinogenesis. Therefore, many targeted agents focusing these gene alterations have been developed and proving their therapeutic efficacies in many clinical trials. Now we should test these gene mutations and should apply treatments individually and properly to ensure the maximal survival benefit of each patient. In this review, we summarize the target genes and respecti

APA, Harvard, Vancouver, ISO, and other styles

40

Lin, Mien-Chun, Cheng-Huang Shen, Deching Chang, and Meilin Wang. "Inhibition of human lung adenocarcinoma growth and metastasis by JC polyomavirus-like particles packaged with an SP-B promoter-driven CD59-specific shRNA." Clinical Science 133, no. 21 (2019): 2159–69. http://dx.doi.org/10.1042/cs20190395.

Full text

Abstract:

Abstract Lung cancer ranks first in both incidence and mortality and is a major health concern worldwide. Upon recognition of specific antigens on tumor cells, complement-dependent cytotoxicity (CDC) is activated, arresting cell growth or inducing apoptosis. However, by overexpressing CD59, a membrane complement regulatory protein (mCRP), lung cancer cells develop resistance to CDC. We previously showed that virus-like particles (VLPs) of human JC polyomavirus (JCPyV) could be used as a gene therapy vector to carry a suicide gene expression plasmid with a lung-specific promoter (SP-B (surfacta

APA, Harvard, Vancouver, ISO, and other styles

41

Sher, Yuh-Pyng, Shih-Jen Liu, Chun-Mien Chang, et al. "Cancer-Targeted BikDD Gene Therapy Elicits Protective Antitumor Immunity against Lung Cancer." Molecular Cancer Therapeutics 10, no. 4 (2011): 637–47. http://dx.doi.org/10.1158/1535-7163.mct-10-0827.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Trudeau, Caroline, Shala Yuan, Jacques Galipeau, Naciba Benlimame, Moulay A. Alaoui-Jamali, and Gerald Batist. "A Novel Parasite-Derived Suicide Gene for Cancer Gene Therapy with Specificity for Lung Cancer Cells." Human Gene Therapy 12, no. 13 (2001): 1673–80. http://dx.doi.org/10.1089/10430340152528165.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Mansorunov, D. Zh, A. A. Alimov, N. V. Apanovich, et al. "GASTRIC CANCER IMMUNOTHERAPY." Russian Journal of Biotherapy 18, no. 4 (2019): 6–16. http://dx.doi.org/10.17650/1726-9784-2019-18-4-06-16.

Full text

Abstract:

Gastric cancer (GC) takes 5th place among the malignant neoplasms by incidence in the world. Mortality from GC is high, since in most cases the disease is diagnosed in the late stages, with distant metastases, the five-year survival in GC does not exceed 25–30 %. The standard for GC therapy is surgery with chemotherapy. There is a high resistance to chemotherapy in the late stages of GC, and this circumstance requires a fundamentally new therapy. Recently, studies have been actively conducted on the therapy of GC with the immune control point inhibitors. At the moment, the most studied are mon

APA, Harvard, Vancouver, ISO, and other styles

44

Scheule, R. K. "Gene Therapy for Lung Cancer--an Application for Cationic Lipid-Mediated Gene Delivery?" JNCI Journal of the National Cancer Institute 90, no. 15 (1998): 1118–19. http://dx.doi.org/10.1093/jnci/90.15.1118.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Rama Ballesteros, A. R., R. Hernández, G. Perazzoli, et al. "Gef Gene: a New Suicide Gene Therapy for Non-Small Cell Lung Cancer." Annals of Oncology 26 (April 2015): i10. http://dx.doi.org/10.1093/annonc/mdv045.15.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Xia, Yu, Xiuqin Li, and Wei Sun. "Applications of Recombinant Adenovirus-p53 Gene Therapy for Cancers in the Clinic in China." Current Gene Therapy 20, no. 2 (2020): 127–41. http://dx.doi.org/10.2174/1566523220999200731003206.

Full text

Abstract:

Suppression of TP53 function is nearly ubiquitous in human cancers, and a significant fraction of cancers have mutations in the TP53 gene itself. Therefore, the wild-type TP53 gene has become an important target gene for transformation research of cancer gene therapy. In 2003, the first anti-tumor gene therapy drug rAd-p53 (recombinant human p53 adenovirus), trade name Gendicine™, was approved by the China Food and Drug Administration (CFDA) for treatment of head and neck squamous cell carcinoma (HNSCC) in combination with radiotherapy. The recombinant human TP53 gene is delivered into cancer

APA, Harvard, Vancouver, ISO, and other styles

47

Crintea, Andreea, Alina Gabriela Dutu, Gabriel Samasca, Ioan Alexandru Florian, Iulia Lupan, and Alexandra Marioara Craciun. "The Nanosystems Involved in Treating Lung Cancer." Life 11, no. 7 (2021): 682. http://dx.doi.org/10.3390/life11070682.

Full text

Abstract:

Even though there are various types of cancer, this pathology as a whole is considered the principal cause of death worldwide. Lung cancer is known as a heterogeneous condition, and it is apparent that genome modification presents a significant role in the occurrence of this disorder. There are conventional procedures that can be utilized against diverse cancer types, such as chemotherapy or radiotherapy, but they are hampered by the numerous side effects. Owing to the many adverse events observed in these therapies, it is imperative to continuously develop new and improved strategies for mana

APA, Harvard, Vancouver, ISO, and other styles

48

Taylor, Kerryn M., David W. Ray, and Paula Sommer. "Glucocorticoid receptors in lung cancer: new perspectives." Journal of Endocrinology 229, no. 1 (2016): R17—R28. http://dx.doi.org/10.1530/joe-15-0496.

Full text

Abstract:

Proper expression of the glucocorticoid receptor (GR) plays an essential role in the development of the lung. GR expression and signalling in the lung is manipulated by administration of synthetic glucocorticoids (Gcs) for the treatment of neonatal, childhood and adult lung diseases. In lung cancers, Gcs are also commonly used as co-treatment during chemotherapy. This review summarises the effect of Gc monotherapy and co-therapy on lung cancers in vitro, in mouse models of lung cancer, in xenograft, ex vivo and in vivo. The disparity between the effects of pre-clinical and in vivo Gc therapy i

APA, Harvard, Vancouver, ISO, and other styles

49

Blumenschein, George R., Gordon B. Mills, and Ana M. Gonzalez-Angulo. "Targeting the Hepatocyte Growth Factor–cMET Axis in Cancer Therapy." Journal of Clinical Oncology 30, no. 26 (2012): 3287–96. http://dx.doi.org/10.1200/jco.2011.40.3774.

Full text

Abstract:

The hepatocyte growth factor (HGF) and its receptor, the transmembrane tyrosine kinase cMET, promote cell proliferation, survival, motility, and invasion as well as morphogenic changes that stimulate tissue repair and regeneration in normal cells but can be co-opted during tumor growth. MET overexpression, with or without gene amplification, has been reported in a variety of human cancers, including breast, lung, and GI malignancies. Furthermore, high levels of HGF and/or cMET correlate with poor prognosis in several tumor types, including breast, ovarian, cervical, gastric, head and neck, and

APA, Harvard, Vancouver, ISO, and other styles

50

Sung, Ji Hyun, Mi-Eun Lee, Seon-Sook Han, Seung-Joon Lee, Kwon-Soo Ha, and Woo Jin Kim. "Gene Expression Profile of Lung Cancer Cells Following Photodynamic Therapy." Tuberculosis and Respiratory Diseases 63, no. 1 (2007): 52. http://dx.doi.org/10.4046/trd.2007.63.1.52.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!